EPRX NASDAQ
Eupraxia Pharmaceuticals Inc.
1W: -9.6%
1M: -2.8%
3M: +11.0%
YTD: -4.4%
1Y: +19.3%
$7.24
-0.59 (-7.54%)
Weekly Expected Move ±12.5%
$5
$6
$7
$8
$9
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$40M
-32.9% ▼
Capital Expenditures
$822K
-688.9% ▼
Free Cash Flow
-$41M
-35.2% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$65M
+372.0% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$18M | -$19M | -$29M | -$26M | -$54M |
| Depreciation & Amort. | $88K | $148K | $156K | $172K | $332K |
| Stock-Based Comp. | $0 | $1M | $1M | $3M | $0 |
| Change in Working Capital | -$167K | $2M | $5M | -$7M | -$996K |
| Other Non-Cash Items | $7M | $1M | $1M | -$880K | $15M |
| Operating Cash Flow | -$12M | -$14M | -$21M | -$30M | -$40M |
| — Investing Activities — | |||||
| Capital Expenditures | -$341K | -$236K | -$73K | -$104K | -$822K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | -$7M | -$3M | $0 | $0 | $0 |
| Investment Sales | $0 | $13M | $0 | $0 | $0 |
| Other Investing | -$4M | $242 | $0 | $29K | $0 |
| Investing Cash Flow | -$11M | $10M | -$73K | -$75K | -$822K |
| — Financing Activities — | |||||
| Net Debt Issuance | $10M | -$142K | -$79K | -$9M | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$69K | $307K | $5M | $363K | $0 |
| Financing Cash Flow | $39M | $11M | $21M | $46M | $106M |
| Net Change in Cash | $16M | $6M | $1M | $14M | $65M |
| Cash End of Period | $17M | $18M | $19M | $33M | $110M |
| Free Cash Flow | -$12M | -$15M | -$21M | -$30M | -$41M |